Drug intelligence / Profile preview

nab-paclitaxel + lobaplatin + S-1 + ramucirumab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This combination involves **nab-paclitaxel**, a nanoparticle albumin-bound formulation of paclitaxel, which stabilizes microtubules to inhibit cell division; **lobaplatin**, a platinum-based chemotherapeutic agent that forms DNA cross-links to inhibit DNA synthesis; **S-1**, an oral fluoropyrimidine derivative that inhibits thymidylate synthase; and **ramucirumab**, a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2), used to inhibit angiogenesis. This combination is being studied for its efficacy in treating advanced gastric cancer.

Targets

TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)

Beyond the preview

Go deeper on nab-paclitaxel + lobaplatin + S-1 + ramucirumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + lobaplatin + S-1 + ramucirumab.

Explore the full profile